Liminal BioSciences Inc., a biopharmaceutical company in its developmental stages, has set its sights on novel treatments for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. Its highly anticipated LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is slated to commence a Phase 1 clinical trial. The company is also conducting preclinical research on OXER1 antagonists and GPR40 agonists. Formerly known as Prometic Life Sciences Inc., Liminal BioSciences Inc. announced its name-change in October 2019. Founded in 1994, the company is headquartered in Laval, Canada.